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spectrometry and high performance liquid chromatography 
analyses of cell extracts and media in the presence and 
absence of NAA established that the acetate moiety pro-
duced by hydrolysis of NAA does not enter mitochondrial 
metabolism in the form of acetyl coenzyme A. We also 
resolved the controversy concerning the possible release 
of aspartate to the medium: aspartate is not released to the 
medium by oligodendrocytes in amounts detectable by our 
methods. Therefore we propose that: aspartate released 
from NAA joins the cytosolic aspartate pool rapidly and 
takes part in the malate–aspartate shuttle, which transports 
reducing equivalents from glycolysis into the mitochondria 
for ATP production and enters the tricarboxylic acid cycle 
at a slow rate.
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Introduction
The brain is an organ with exceptionally high energy 
demands and relies on an uninterrupted supply of substrates 
for oxidative phosphorylation in mitochondria. Around 25 % 
of the body’s to al glucose budget is spent on processes in 
the br in, including the generation of action potentials and 
synaptic transmission [1]. Glucose-derived energy is there-
fore of utmost importance for maintaining physiological 
function of the brain. In contrast, many neurodegenerative 
diseases including Alzheimer’s disease [2] are associated 
with compromised glucose metabolism and markers of low 
energy status. Quantification of N-acetylaspartate (NAA) 
has often been used to assess the metabolic integrity of 
n urons [3, 4]. NAA can be detected by 1H-magn tic reso-
nance spectroscopy, and has been applied as a non-invasive 
Abstract Oligodendroglial cells are known to de-acety-
late the N-acetylaspartate (NAA) synthesiz d and released 
by neurons and use it for lipid synthesis. However, the role 
of NAA regarding their intermediary metab i m remains 
poorly understood. Two hypotheses were proposed regard-
ing the fate of aspartate after being released by de-acet-
ylation: (1) aspartate is metabolized in the mitochondria 
of oligodendrocyte lineage cells; (2) aspartate is released 
to the medium. We report her  that aspartoacylase mRNA 
expression increases when primary rat oligodendrocyte 
progenitor cells (OPCs) differentiate into mature c ll  in 
culture. Moreover, characte ising metabolic functions of 
acetyl coenzyme A and aspartate from NAA atabolism in 
mature oligodendrocyte cultures afte  5 days using isotope-
labelled glucose after 5-days of differentiation we found 
evidence of extensive NAA metabolism. In ub tio  with 
[1,6-13C]glucose followed by gas chrom tography–mass 
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spectrometry (GC–MS) and high performance liquid 
chromatography (HPLC). We found that the acetyl CoA 
produced by hydrolysis of NAA does not enter mitochon-
drial metabolism. We propose that the aspartate joins the 
aspartate pool active in the malate–aspartate shuttle and we 
established that aspartate is not released to the medium in 
amounts detectable by our methods.
Materials and Methods
Materials
Cell culture reagents were purchased from Sigma (Dorset, 
UK)—Dulbecco’s modified Eagle’s medium (DMEM), 
minimum essential medium Eagle (MEM), l-gl tamine,
poly--lysine (PLL), papain, NAA—or Life Technologies 
(Paisley, UK)—fetal bovine serum (FBS), penicillin–strep-
tomycin (pen–strep), trypsin–EDTA, phosphate buffered 
saline (PBS). 13C-labelled compounds were obtained from 
Cambridge Isotope Laboratories, MA, USA. The mass 
spectrometry derivatization reagents MTBSTFA (N-methyl-
N-(tert-butyldimethylsilyl) trifluoroacetamide), MSTFA 
(N-methyl-N-(trimethylsilyl) trifluoroacetamide) and the 
t-BDMS-Cl (tert-butyldimethylchlorosilane) were pur-
chased from Regis Technologies, Inc. (Morton Grove, IL, 
USA). Recombinant human PDGF-AA and Recombinant 
human FGF-basic were purchased from PeproTech (Rocky 
Hill, NJ). All other chemicals were of the purest grade avail-
able from Sigma (Dorset, UK).
Primary Cultures of Rat Oligodendrocytes
Primary mixed glia cultures were isolated from neonatal 
Sprague Dawley rat (postnatal day 0–2) forebrains follow-
ing established protocols [29]. Briefly, pups were eutha-
nized according to “Schedule 1” regulations from the Home 
Office Animal Procedures Committee UK. Cells were cul-
tured for 10–15 days in DMEM supplemented with 10 % 
FBS, 1 % pen-strep and 4 mM glutamine, and kept under 
a humidified atmosphere at 37 °C and 7 % CO2. Oligoden-
drocyte precursor cells (OPCs) were subsequently isolated 
using a step-based shake-off protocol and cultured in Sato’s 
medium on PLL-coated plates [29]. To obtain immature 
OPCs, cells were cultured for 1 day in Sato’s medium sup-
plemented with human PDGF-AA and human recombinant 
FGF at 10 ng/ml. To induce differentiation, OPCs were cul-
tured in Sato’s medium supplemented with 0.5 % fetal calf 
serum (FCS) for 1 or 5 days. The cell culture medium was 
replaced by fresh medium at day two of differentiation. For 
all experiments only cultures with > 93 % purity (determ ned 
based on O4 immunostaining) were used [30].
quantitative method for detecting progression, recovery, 
and remission in an ever-in reasing c talogue of disorders 
of the brain [5]. However, the fundamental role of NAA in 
the brain remains elusive and the av ilable evidence for its 
function is limited to a role in providing acetyl groups for 
lipid synthesis [6].
NAA is amongst the most abundant amino acid deriva-
tives in the brain and is synthesized from aspartate and ace-
tyl coenzyme A (CoA) by aspartate N-acetyltransferase [7]. 
After birth, NAA content in the brain i subjec  to a rapid 
increase to reach concentrations of 5 to 10 mM [8, 9], being 
especially concentrated in gray matter-rich regions [9–12]. 
NAA synthesis is dependent on mitochondrial integrity [7, 
13] and fluctuations in concentration can occur in parallel 
with changes in adenosine triphosphate (ATP) [14], sug-
gesting an intimate relationship with me abolic energy.
NAA is produced by and released from neurons. These 
depend on the supply of precursor molecules provided by 
astrocytes to synthesize the aspartate nec ssary for NAA 
production [15, 16]. NAA is metabolized in oligod ndro-
cytes, which contain aspartoacylas (ASPA) [17–19], the 
only known NAA-catabolizing enzyme in the b ain. The 
importance of ASPA to myelination is hig ghted by the 
severely dys-myelinated phenotype of the inh rite  human 
paediatric leukodystrophy, Canavan disease (CD), which 
results from the loss of ASPA function. The abnormal y 
high levels of NAA in CD are in contrast to abnormally low 
levels of NAA that typically are seen in practically ll other 
neurodegenerative diseases. Considering the importance of 
NAA as a prognostic marker of metabolic function across a 
wide pathological range the view that NAA solely acts as a 
shuttle for acetyl groups during lipid synthesis may there-
fore be insufficient. Multiple roles have been suggested for 
NAA such as: being an osmolyte that acts as a “molecu-
lar water pump” to remove met bolica l produced water 
from neurons [20, 21]; in addition to moving acetate groups 
across the mitochondrial membrane system, NAA also acts 
by moving nitrogen groups to the cytoplasm [22]; NAA 
is involved in facilitating glutamine/glutamate oxidation 
in neuronal mitochondria, while bypassing the glutam te 
dehydrogenase reaction and th refor  avoiding amm-
nia production [23]; being a storage and transport form of 
acetate [24]. Other proposed roles include the involvement 
in histone and protein acetylation reactions [25]; altering 
metabolism (aerobic glycolysis and Warburg effect) in can-
cer cells [26, 27] and, more recently, it was linked to neuro
nal differentiation [28].
In order to investigate the ole of NAA in intermedi ry 
metabolism, we incubated cultures enriched for mature oli-
godendrocytes in medium containing [1,6-13C]glucose for 8 
and 24 h in the presence and abs nc  of NAA and analysed 
cell extracts and media using gas chro at gr phy–mass 
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High Performance Liquid Chromatography (HPLC)
HPLC was used to quantify the total amounts of amino acids 
in samples of cell extracts. Samples were lyophilized and 
re-suspended in 0.01 M HCl and subsequently derivatised 
with o-Phthaldialdehyde [32] using an automated method 
prior to injection into the HPLC column. Amino acid con-
centrations were determined by comparison to a calibration 
curve of standard solutions of amino acids run after every 12 
samples. Analyses were performed on 6–11 samples derived 
from three independently generated cultures. For details see 
Amaral et al. [32].
Gas Chromatography–Mass Spectrometry (GC–MS)
For analysis of percent enrichment with 13C in lactate, 
amino acids (aspartate, glutamate and glutamine) and 
TCA cycle intermediate (citrate) after incubation with 
[1,6-13C]glucose ± NAA, cell extracts and samples of 
medium were lyophilized and re-suspended in 0.01 M 
HCl. Derivatisation with MTBSTFA in the presence of 1 % 
t-BDMS-Cl [33] was performed as described in Amaral et 
al. [30]. The samples were analysed on an Agilent 6890 gas 
chromatograph connected to an Agilent 5975B mass spec-
trometer (Agilent Technologies, Palo Alto, CA). The parent 
ion (M) and atom percent excess for one 13C atom (M + 1)
values for lactate, citrate, glutamate, glutamine and aspar-
tate were calculated from the GC–MS data using the Mass-
Hunter software supplied by Agilent (Agilent Technologies, 
Palo Alto, CA) and correcting for the naturally abundant 13C 
by using non-enriched standards [34]. Analyses were per-
formed on 6–12 samples of medium and 8–11 samples of 
extracts derived from four independently generated cultures.
Statistical Analysis
Statistical analysis was conducted using unpaired two-tailed 
Student t tests (confidence interval = 95 %) to compare the 
effect of NAA on the intracellular amounts of amino acids, 
on enrichment in 13C i  extracellular and intracellular 
metabolites and on the glucose consumption and lactate 
release rates. To evaluate differences in the expression of 
ASPA mRNA levels at different stages of OPC maturation 
in culture, a one-way ANOVA (alpha = 0.05) followed by 
Tukey’s multiple comparison test was performed.
Results
To investigate how NAA is metabolised by mature oligoden-
drocytes, we incubated primary OPC cultures maintained in 
differentiation medium for 5 days with [1,6-13C]glucose in 
the presence or absence of NAA. By assessing differences 
Quantitative Reverse Transcriptase PCR
To determine the mRNA levels of ASPA during OPC differ-
entiation, cells were cultured eith r for 1 day in proliferation 
medium, or for 1 or 5 days in differentiation medium. Total 
RNA was extracted using the RNeasy Mini Kit (Qiag n, 
Manchester, UK). cDNA was synthes zed from 20 ng RNA 
per sample using the Maxima First Strand cDNA Synth sis 
Kit (Thermo Scientific, Waltham, MA USA). Quantitative 
PCR (qPCR) was conducted as previously out in d [29] on 
an Applied Biosystems 7500HT Fast Real-time PCR system. 
The primers used were: ASPA F-AGACGTGGCTGCTGT-
TATCC; ASPA R-GATCTCCAGGGTGCAATGGT; beta 
actin F-CATGGCATTGTGATGGACT; beta actin R-ACG-
GATGTCAACGTCACACT. Values are represented as ASPA/
beta actin ratios. Measurements were made on 8–11 samples 
obtained from three independently generated cultures.
Incubations with 13C Labelled Glucose and NAA
OPCs isolated from mixed glia cultures were cultured in 6 
well plates at a cell densi y of 4×105 cells/well and a lowed 
to differentiate for 5 days (see above for details). Prior to 
incubation, cells were washed nce with PBS a d incubated 
with 2 ml Sato’s medium prepared from a glucose, gluta-
mine and pyruvate-free DMEM (S gma D5030, Dorset, UK) 
supplemented with 0.5 % FCS and 2 mM [1,6-13C]glucose, 
2 mM glutamine and 2 mM NAA (controls did not have 
NAA in the incubation medium) for 8 and 24 h. Samples of
medium were collected before and after the incubation period
and subsequently analysed by ma s spectrometry. To stop the
incubation, cells were washed twice with cold PBS and the 
intracellular metabolites ed with 70 % ethanol [31]. 
Experiments were performed in four independently gener-
ated cultures with, at least, two replicate wells per condition.
Glucose and Lactate Analyses
Glucose and lactate levels in the cell cul ure medium were 
analysed at the Core Biochemical Assay Laboratory, Clini-
cal Biochemistry, Addenbrooke’s Hospital using automated 
assays on a Siemens Dimension RxL analyser. The rate of
glucose and lactate net change r lative to cells over time 
(µmol/106 cells/24 h) was calculated by subtracting the 
value measured at the end of the experiment (T = 24 h) from 
the one measured in a sample of medium collected at the 
onset of the incubation, and dividing the resulting value by 
the amount of cells in each experiment, multiplied by the 
experimental volume (2 ml). The cell number considered 
in the calculations was the cell number at plat ng since oli-
godendrocytes do not proliferate. Analyses were performed




not affected at 8 h (Fig. 5). All other metabolites displayed 
an increase in 13C enrichment after 8 h incubation with 
[1,6-13C]glucose and NAA as compared to cultures that did 
not receive NAA (Fig. 5).
Discussion
Glucose metabolism in neurons and astrocytes has been 
studied extensively and much is known about the interac-
tion between these two cell types in the brain [35]. How-
ever, until very recently oligodendrocytes have not been 
studied in this context [30, 35–38].
It was evident that the metabolism of N-acetylaspartyl-
glutamate (NAAG) has a tri-cellular compartmentation, 
however, this was not clear in regard to NAA [38–40]. Both 
NAA and NAAG are synthesized by neurons in the brain. 
Neurons release both NAA and NAAG to the extracellular 
space upon stimulation, where astrocytes, the target cells for 
NAAG, hydrolyse it, releasing NAA, which is subsequently 
catabolised in oligodendrocytes. It has been proposed that 
oligodendrocytes release the aspartate obtained from NAA 
for recycling to neurons [39]. This hypothesis assumes that 
aspartate produced from NAA is passed from oligodendro-
cytes back to neurons to be reutilized for re-synthesis of 
NAA and NAAG. This exchange of metabolites would be 
in analogy with the well-established glutamine–glutamate 
cycle between glia and neurons [35]. Existing evidence 
suggests that the aspartate derived by catabolism of NAA 
in the brain may not be used for the re-synthesis of NAA 
[22]. Studies demonstrated rapid transamination of dou-
bly labelled (3H and 15N) aspartate from [3H 2
15N]NAA, in
which the amino group was transferred to glutamate, in the 
absence of 15N-NAA production. However, Miller et al. [22] 
could not follow the carbon skeleton of NAA since the nitro-
gen was labelled, not the carbon atoms. Our results, using a 
13carbon labelled precursor ([1,6-13C]glucose), demonstrate 
that aspartate is not released to the medium by oligodendro-
cytes in culture, disproving the hypothesis of aspartate recy-
cling between neurons and oligodendrocytes [39]. What we 
observed was an increase in aspartate content in the oligo-
dendrocytes but the % 13C labelling remained unchanged. 
It is likely that aspartate is converted to oxaloacetate and 
further to malate in the cytosol, steps in the energy produc-
ing malate-aspartate shuttle for transporting reducing equiv-
alents from NADH from glycolysis into the mitochondria 
[35]. The malate–aspartate shuttle is tightly coupled to gly-
colysis in that reducing equivalents are transported into the 
mitochondria for oxidative phosphorylation. Therefore, ATP 
is produced and NAD, which is necessary for glycolysis, 
is re-generated in the cytosol. The increased glucose con-
sumption and lactate production observed in the presence 
of NAA in the present study is indicative of an increased 
in metabolite enrichment i  13C, th s strategy enabled us 
to study aspartate and acetate, both metabolic products of 
NAA, in metabolic pathways of glucose. For detail on 13C 
labelling Fig. 1a. [1,6-13C]Glucose is taken up by oligoden-
drocytes and converted to 2 molecules of [3-13C]pyruvate via 
glycolysis. Lactate dehydrogenase converts [3-13C]p ruvate 
to [3-13C]lactate or [3-13C]py uvate, which can enter the 
mitochondria to be further metabolized to [2-13C]ac tyl 
CoA and enter the TCA cycle. The subsequent TCA cycle 
metabolites and amino acids deriv d from oxaloacetate
and α-ketoglutarate, aspartate and glutamate, respectively, 
will be labelled with one 13C atom, resulting in mass M + 1. 
When a labelled acetyl CoA molecule condenses with a 
labelled oxaloacetate molecule th  subsequen metabolites 
will contain two 13C toms which will result in mass M + 2. 
Apart from its role in the TCA cycl , citrate is used to fu nel 
acetyl CoA units into lipid synthesis. Figure 1b provides an 
overview of the metabolic pathways asse sed in the present 
study. We postulated that oligodendrocy es possess distinc  
mitochondria or TCA cycles that a e sp c alised for lipid 
synthesis and others that priorit  energy an  amino acid 
production (Fig. 1b). When NAA enters the cell it is hydro-
lyzed into acetyl CoA and aspartate by ASPA. Whereas 
acetate is used for lipid synthesis (Fig. 1b), aspartate c n 
then participate in the mala –aspartate shuttle (for details 
see [32]) or/and enter the TCA cycle after conversi n to 
oxaloacetate.
In order to verify that the oligodendrocyte cultures used
in the present study expre sed the enzyme responsibl  fo  
NAA hydrolysis, we quantified the ASPA mRNA levels. 
This demonstrated an increase in ASPA mRNA expres ion 
from day 1 to day 5 of differentiation (Fig. 2). All subse-
quent experiments were performed on 5-day- ld c ltures.
Cells were incubated in m dium conta ning 
[1,6-13C]glucose for 8 and 24 h in the presence and absence 
of NAA. The presence of NAA increased glucose con-
sumption and lactate production (Fig. 3a, b). Th  the ti-
cal maximum enrichment of lac ate f om [1,6-13C]glucose 
is 100 %. However, after 8 h only approximately 50% of 
lactate was 13C labelled, reaching approximately 65 % after 
24 h (Fig. 3c, d). The addition of NAA did not affect 13C 
enrichment in lactate (Fig. 3c, d). Similarly, 13C-enrich d
citrate was released to the medium, but its enrichment was 
not affected by the addition of NAA (Fig. 3e, f).
The intracellular amounts of spart te, glutamine and 
glutamate after 8 and 24 h incuba ion are provided in Fig. 4.
Aspartate was increased in the presence of NAA whereas 
glutamine and glutamate were not (Fig. 4).
Analysis of 13C incorporation from [1,6-13C]gluc se into 
intracellular metabolites was c nducted after 8 and 24 h in 
the absence or presence of NAA (Fig. 5). No differences 
were detected in 13C enrichment in any metabolite anal-
ysed after 24 h (Fig. 5) and aspartate and citra e were also 
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Fig. 1 a 13C glucose labelling patterns in oligodendrocytes. 
[1,6-13C]Glucose is taken up by oligodendrocytes and converted to 2 
molecules of [3-13C]pyruvate via glycolysis. Lactate dehydrogenase 
converts [3-13C]pyruvate to [3-13C]lactate (LAC) and alanine amino-
transferase to alanine (ALA). Alternatively, [3-13C]pyruvate can enter 
the mitochondria to be metabolized to [2-13C]acetyl CoA which can 
enter the TCA cycle. The subsequent TCA cycle metabolites such as: 
citrate, malate (MAL) and oxaloacetate (OAA) and amino acids such 
as aspartate (ASP), glutamate (GLU) and glutamine (GLN), will be 
labelled with one 13C atom, r sulting in an increase in the parent ion 
M mass to M + 1, which can be detected by GC–MS. b Schematic pre-
sentation of glucose metabolism in oligodendrocytes in the presence 
of NAA. We propose that at least two distinct TCA cycles exist: (1) 
one TCA cycle (depicted on the left) n which most of the energy is 
produced and in which only a fraction of citrate leaves the cycle and 
co tr butes t  lipid synthesis. This “energy producing” TCA cycle is 
halted by the presence of NAA, which results in increased labelling 
of e.g. glutamate and glutamine and, to a lesser degree, citrate. The 
spartate derived from NAA does not enter into this (1) TCA cycle 
during the initial phase (up to 8 h), since this would reduce labelling 
of glutamate and glutamine. In contrast, we found that labelling of 
glutamate and glutamine increased but labelling of aspartate did not 
increase. These findings indic te that the aspartate derived from NAA 
e ters he malate–aspartate shuttle and dilutes aspartate labelling. (2) 
A second TCA cycle is impl ed by the increased 13C abelling of citr t  
in the medium, which occurred much more extensively than labelling 
of other metabolites after 24 h incubation with [1,6-13C]glucos . The 
citrate producing TCA cycle for lipid synthesis was not affected by 





cell lines [41]. A potential explanation consists in a more 
efficient NAD regeneration due to an increase in the capac-
ity of the malate–aspartate shuttle due to aspartate genera-
tion from NAA. Entry of aspartate from NAA into the TCA 
cycle appears to be slow due to the expected dilution of 13C 
labelling of compounds derived from this cycle, and conse-
quently % enrichment, was not decreased after 8 h of incu-
bation. Aspartate labelling would be expected to increase 
together with glutamate and glutamine at 8 h, but this was 
not observed. Indeed, % 13C lab lling of aspartate was 
unchanged, indicating that aspartate synthesis from NAA 
took place in a restricted compartment, which we hypoth-
esise to be the malate-aspartate shuttle. However, after 24 h 
incubation with NAA the labelling of glutamate and gluta-
mine was not found to be different from the one observed in 
cells cultured in the absence of NAA, indicating that aspar-
tate was participating in the TCA cycle. This observation 
may also be related to the slow turnover of NAA detected in 
vivo. The reported turnover rates of NAA C6 and C3 in rat 
brain range between 0.7 ± 0.1 and 0.6 ± 0.1 µmol/(g h) with 
aerobic glycolysis (Warburg effect) also seen in cancer cells. 
In this context it is noteworthy that exog nously applied 
NAA has been found to promote growth in several cancer 
Fig. 2 Aspartoacylase (ASPA) mRNA levels during OPC differen-
tiation in vitro. Cells were cultured either for 1 day in proliferation 
medium, or for 1 or 5 days in differentiation mediu . Valu s are ep-
resented as ASPA/beta actin ratios. Measurements were made on 8–12 
samples obtained from three independently generated cultures (for 
details see “Methods” section)
 
Fig. 3 Effect of NAA on 
glucose consumption, lactate 
release, and enrichment with 
13C of extracellular metabolites 
in mature oligodendrocyte 
cultures. Oligodendrocytes were 
incubated in medium contain-
ing [1,6-13C]glucose, 2 mM 
glutamine and 2 mM N-acetyl
aspartate (NAA). Controls did 
not have NAA in the incubation 
medium. Samples of medium 
were collected and subsequently 
analysed by gas chromatog-
raphy–mass spectrometry. % 
13C enrichment above natural 
abundance is given for lactate 
(LAC) and citrate (CIT) after 8 
or 24 h of incubation. Experi-
ments were performed on 6–12 
samples, which derived from 
four independently generated 
cultures. Glucose consump-
tion and lactate release were 
measured in 9–12 samples 
obtained from four indepen-
dently generated cultures after 





CoA since this would have resulted in decreased 13C lab l-
ling of the metabolites, and this was not observed. This is in 
agreement with a report that oligodendrocytes do not have 
the mitochondrial enzyme AceCS2 [4]. Howev r, in the 
mitochondria of oligodendrocytes in culture, we have shown 
that acetate from the medium is indeed converted to acetyl 
CoA [30]. As previously mentioned, the most likely fate of 
the resulting acetyl CoA is its entry into lipid synthesis [6].
Tri-Cellular Compartmentation of NAA Metabolism?
Tri-cellular compartmentation is necessary for catabo-
lism of NAAG but not for NAA. For the latter, interac-
tions between neurons and oligodendrocytes appear to be 
sufficient. However, it is important to note that aspartate 
production in neurons is only possible with the help of 
glutamine from other cells. Neurons do not express pyru-
vate carboxylase, the anaplerotic enzyme in the brain [15] 
and, thus, cannot produce “de novo” aspartate. In order to 
export NAA, neurons have to import glutamine from exter-
nal sources [45]. Aspartate is synthesized in the TCA cycle 
as a result of multiple conversion steps involving glutamate 
and oxaloacetate. So far only astrocytes are known to syn-
thesise glutamine “de novo” and to release it to the medium 
[35]. We have recently demonstrated that oligodendro-
cytes are capable of anaplerosis [32] and therefore meet 
one of the requirements for supporting neurons. However, 
it remains unknown whether they are capable of exporting 
glutamine and, so, support transfer of NAA. Our present 
findings indicate a tri-cellular compartmentation of NAA 
metabolism, which starts with astrocytes releasing gluta-
mine, which is taken by neurons, and converted into NAA. 
Subsequently, NAA released into the extracellular space is 
taken up and metabolized by oligodendrocytes. Figure 6 
the time constants 14 ± 2 and 13 ± 2 h, respectively, with an 
estimated pool size of 8 µmol/g [42]. These resul s suggest 
that complete label turnover of NAA from glucos  ccurs in 
approximately 70 h. This is in agreement w th a slow incor-
poration of aspartate into the oligodendrocyte TCA cycle in 
order to maintain homeostasis between synthesis an  deg-
radation. A potential explanation for the increas  in % 13C 
labelling in glutamate and glutamine is a decrease in the 
amount of 13C labelled citrate leaving the TCA cycle as the 
acetyl CoA content in the cytosol is increased due to the 
catabolism of NAA. The reduced leakage of labelled sub-
stance is expected to cause an overa l incre se in l belling.
Percent 13C labelling of glutamate and glutamine were 
increased in the presence of NAA. This may be caused by a 
decrease in 13C labelled citrate efflux from the TCA cycle to 
the cytosol. Citrate is the most ommon prec sor for acetyl 
CoA production in the cytosol, and also acts as a substrate for 
lipid synthesis. High levels of NAA in the cytosol of oligo-
dendrocytes incubated with NAA could support acetyl CoA 
production from acetate generated by hydrolysis of NAA. 
This is a possibility since ACSS2, the gene for the nuclear-
cytosolic form of acyl-CoA synthetase short-chain family 
member, is expressed in oligo endrocytes o a high extent 
as reported in transcriptomics studies of the mouse brai  [43, 
44]. This would decrease the need for citrate catabolism for 
fatty acid synthesis. In contrast to the increased enrichment 
of glutamate and glutamine, no differences in the labelling f 
citrate inside the cells and in the medium were d ected. This 
indicates that the majority of citrate was produced in a sepa-
rate compartment. The notio  of ompartmentati n is also 
supported by the much larger % 13C enrichment in citrate
in the medium compared to that of intracellular metabolites.
It is unlikely that the acetat  moiet  of NAA r leased by
ASPA entered the mitochondria and was co verted to acetyl 
Fig. 4 Effect of NAA on the intracellular levels of amino acids in 
mature oligodendrocyte cultures. HPLC was used to quantify the 
amounts of aspartate (ASP), glutamate (GLU) and glutamine (GLN) 
in samples of cell extracts of oligodendrocytes cultured for 5 days 
in differentiation medium and incubated for 24 h in the presence or 
absenc  of 2 mM N-acetyl aspartate (NAA). Analyses were performed 
on 6–11 sampl s, which derived from three independently generated 





various cell types in the brain associated with NAA syn-
thesis and breakdown [4, 46]. The authors stressed that the 
slow rate of NAA synthesis in neurons and breakdown and 
summarizes the findings described in the present work. A 
similar multicellular metabolism of NAA h s been p o-
posed depicting some of the metabolite trafficking between 
Fig. 5 Effect of NAA on 
[1,6-13C]glucose-derived 
enrichment with 13C in ntracel-
lular metabolites of mature 
oligodendrocytes. Oligodendro-
cytes differentiated for 5 days 
were incubated in medium con-
taining [1,6-13C]glucose, 2 mM 
glutamine and 2 mM N-acetyl
aspartate (NAA). Controls did 
not have NAA in the incuba-
tion medium. Cell extracts were 
collected and subsequently 
analysed by gas chromatog-
raphy–mass spectrometry. % 
13C enrichment above natural 
abundance is given for aspartate 
(ASP), glutamate (GLU), gluta-
mine (GLN), citrate (CIT) and 
malate (MAL) after 8 or 24 h of 
incubation. Experiments were 
performed on 8–11 samples, 
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